Patents by Inventor Gregory J. LaRosa

Gregory J. LaRosa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CCR2 antibodies and methods of use therefor
    Publication number: 20020051781
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: June 29, 2001
    Publication date: May 2, 2002
    Inventor: Gregory J. LaRosa
  • Anti-CCR2 antibodies and methods of use therefor
    Publication number: 20020037285
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: May 29, 2001
    Publication date: March 28, 2002
    Inventor: Gregory J. LaRosa
  • Anti-CCR2 antibodies and methods of use therefor
    Publication number: 20020028436
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: July 13, 2001
    Publication date: March 7, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Anti-CCR2 antibodies and methods of use therefor
    Patent number: 6352832
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: July 22, 1999
    Date of Patent: March 5, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman
  • Anti-CCR2 antibodies and methods of use therefor
    Publication number: 20020015700
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: July 13, 2001
    Publication date: February 7, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Anti-CCR2 antibodies and methods of use therefor
    Publication number: 20020012664
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Application
    Filed: July 13, 2001
    Publication date: January 31, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Anti-CCR2 antibodies and methods of use therefor
    Patent number: 6312689
    Abstract: The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: July 23, 1998
    Date of Patent: November 6, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Gregory J. LaRosa
  • Chemokine-like proteins and methods of use
    Patent number: 5789539
    Abstract: The invention relates to novel chemokine-like proteins that include two or more newly discovered active domains from different chemokines. Active domains are regions of several contiguous amino acids that are necessary for chemokines' ability to suppress the proliferation of actively dividing myeloid cells, e.g., myeloid progenitor cells, myeloid stem cells, and leukemic cells. The new chemokine-like proteins provide higher myelosuppressive activity than naturally occurring, wild-type chemokines.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 4, 1998
    Assignee: Repligen Corporation
    Inventors: Thomas J. Daly, Gregory J. LaRosa
  • Chemokine-like proteins and methods of use
    Patent number: 5656724
    Abstract: The invention relates to novel chemokine-like proteins that include two or more newly discovered active domains from different chemokines. Active domains are regions of several contiguous amino acids that are necessary for chemokines' ability to suppress the proliferation of actively dividing myeloid cells, e.g., myeloid progenitor cells, myeloid stem cells, and leukemic cells. The new chemokine-like proteins provide higher myelosuppressive activity than naturally occurring, wild-type chemokines.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: August 12, 1997
    Assignee: Repligen Corporation
    Inventors: Thomas J. Daly, Gregory J. LaRosa